Chronic myeloid leukaemia (CML) in remission represents a remarkable success story in modern cancer care. When the disease is well controlled through treatment, many patients can now achieve sustained remission—a state where tests no longer detect signs of leukaemia in the blood or bone marrow. For some, this control is so deep and lasting that doctors may even discuss the possibility of stopping treatment altogether, allowing patients to live medication-free while being carefully monitored.

Living Beyond Daily Tablets: What Remission Means for People with CML

When chronic myeloid leukaemia responds well to treatment, the primary goal shifts from simply controlling the disease to maintaining a state where leukaemia cells are no longer detectable in standard tests. This achievement is called remission, though it does not mean the disease has completely vanished from the body. Rather, it indicates that medical treatments have reduced leukaemia cells to levels so low that they cannot be found through routine blood monitoring. The outlook for people with CML has transformed dramatically over recent decades—in the 1970s, only about one in five patients survived five years after diagnosis, but by 2017, this figure had risen to more than seven in ten.^[1]

Remission in CML is typically divided into different levels based on how deeply the disease has been suppressed. Molecular remission is the deepest form, meaning that even the most sensitive genetic tests cannot find the BCR-ABL1 gene—the abnormal gene that drives CML—in blood or bone marrow samples. Achieving this deep level of control usually requires several years of continuous treatment with medications called tyrosine kinase inhibitors, which block the abnormal protein produced by cancer cells.^[6]

The focus of treatment in remission is maintaining this suppressed state while minimising the impact of medication on daily life. For many patients, this balance means taking a daily tablet indefinitely, but recent research has shown that under certain conditions, some patients can safely stop their medication for extended periods without the disease returning. This possibility has fundamentally changed how doctors and patients think about long-term management of CML, shifting from lifelong treatment to the prospect of treatment-free intervals or even indefinite breaks.^[4]

Standard Treatment: The Medications That Keep CML Under Control

The cornerstone of CML treatment, both during active disease and in maintaining remission, consists of tyrosine kinase inhibitors (TKIs). These medications work by targeting a specific abnormal protein created by the BCR-ABL gene fusion that occurs in CML cells. This genetic abnormality, known as the Philadelphia chromosome, appears in virtually all people with CML and produces a protein that tells bone marrow to create too many abnormal white blood cells. TKIs act like highly specific switches that turn off this faulty signalling, preventing cancer cells from multiplying uncontrollably.^[2]

The first TKI approved for CML was imatinib, which revolutionised treatment when it became available around 2001. This medication transformed CML from a potentially fatal disease into a manageable chronic condition. Since then, several newer TKIs have been developed, including second-generation drugs such as dasatinib, nilotinib, and bosutinib, and third-generation options like ponatinib. Each of these medications targets the same abnormal protein but differs in potency, side effect profiles, and effectiveness against specific genetic mutations that can develop in CML cells over time.^[5]

Most patients take their TKI tablet once daily, though dosing schedules vary depending on the specific drug prescribed. The choice of which TKI to use depends on multiple factors including the patient’s age, other health conditions, potential side effects, and how aggressively the disease needs to be controlled. Imatinib remains widely used as initial treatment, particularly in resource-limited settings, while newer TKIs may be chosen for patients who need faster or deeper responses.^[16]

Side effects from TKIs are common, though they vary considerably between different medications and individual patients. Common problems include fluid retention and swelling, particularly with imatinib; muscle and joint pain; gastrointestinal symptoms such as nausea and diarrhoea; fatigue; and skin rashes. Some TKIs can affect heart function or blood vessels, requiring careful monitoring. Certain medications, like hydroxycarbamide sometimes used alongside TKIs, can make skin more sensitive to sunlight, increasing the risk of burns or skin damage. Most side effects are manageable and tend to lessen over time, though some patients may need to switch medications if problems persist.^[14][21]

The duration of treatment with TKIs traditionally has been lifelong, even when tests show no detectable disease. This approach ensures that any remaining leukaemia cells stay suppressed and cannot multiply. However, recent clinical research has challenged this assumption, showing that some patients who achieve very deep and sustained remissions can safely stop their medication under careful medical supervision. This development has opened a new chapter in CML care, though it applies only to selected patients who meet strict criteria.^[3]

Treatment-Free Remission: The Possibility of Life Without Daily Medication

One of the most significant advances in CML care over the past decade has been the concept of treatment-free remission, sometimes called a treatment break. This refers to the ability of some patients to stop taking their TKI medication and remain in remission without any signs of disease returning, as long as they continue regular monitoring. The possibility emerged from clinical trials that began around 2007, when researchers started investigating whether patients with exceptionally good responses to treatment could safely discontinue their medication.^[4]

To be considered for a treatment break, patients must meet several strict criteria. Most guidelines specify that patients should have been taking TKIs for at least three to five years and should have achieved a very deep molecular response—meaning that sensitive tests have not detected the BCR-ABL1 gene for at least two consecutive years. Additionally, candidates should not have experienced accelerated or blast phase CML, should not have certain chromosomal abnormalities beyond the Philadelphia chromosome, and must be willing and able to comply with intensive monitoring after stopping treatment.^[3][6]

Some doctors may recommend gradually reducing the TKI dose over approximately twelve months before stopping completely, though others proceed with immediate cessation. When patients stop taking TKIs, they may experience withdrawal syndrome—a collection of symptoms including muscle and joint aches and generally feeling unwell. These symptoms are usually mild and temporary, often resolving within weeks. Non-steroidal anti-inflammatory drugs can help manage discomfort, and only rarely do these symptoms require restarting the TKI.^[3]

After stopping treatment, monitoring becomes crucial. Patients typically have PCR blood tests—which detect the BCR-ABL1 gene with extreme sensitivity—every month for the first six months, then every six to eight weeks for the next six months, and every two to three months thereafter. This intensive schedule is necessary because if the disease returns, it usually does so within the first six months after stopping medication. Most recurrences occur within the first two years, though late relapses are possible, which is why lifelong monitoring continues even in patients who remain disease-free.^[11]

Clinical trials have shown that approximately half of patients who meet the criteria for stopping treatment can remain in remission without medication. For those whose tests start showing detectable BCR-ABL1 again, restarting the same TKI almost always brings the disease back under control quickly. Studies over the past ten to fifteen years have demonstrated that when treatment is resumed early after molecular recurrence, the chance of achieving deep remission again approaches 100 percent. Importantly, there is no evidence that stopping and then restarting treatment causes harm or makes the disease harder to control.^[6][13]

The reasons why treatment-free remission succeeds for some patients but not others remain under investigation. Researchers believe that the immune system plays a crucial role—patients who achieve lasting treatment-free remission may have immune responses that help keep any remaining leukaemia cells in check even without medication. Understanding these mechanisms better could help identify which patients are most likely to succeed off treatment and might point toward strategies to improve the success rate, possibly through immune-boosting therapies.^[4]

Not all patients who are eligible for treatment-free remission choose to pursue it. Some prefer the security of continuing daily medication rather than facing the anxiety of potential relapse. Others are motivated to stop by treatment side effects, financial considerations, the desire to start a family, or simply the wish to live without the daily reminder of having cancer. The decision is highly personal and should be made collaboratively between patient and doctor, weighing the benefits of being medication-free against the demands of intensive monitoring and the possibility of needing to restart treatment.^[3][13]

Treatment in Clinical Trials: Exploring New Approaches

While standard TKI therapy has dramatically improved outcomes for people with CML, researchers continue investigating new treatments and strategies through clinical trials. These studies aim to improve remission rates, reduce side effects, increase the proportion of patients who can safely stop treatment, and ultimately move closer to the goal of curing CML rather than simply controlling it.^[4]

One recently developed medication is asciminib, a novel type of TKI that works differently from earlier drugs. While traditional TKIs target the active site of the BCR-ABL protein where it performs its function, asciminib binds to a different region called the ABL myristoyl pocket. This unique mechanism may be particularly useful for patients who have developed resistance to other TKIs or who cannot tolerate them. Asciminib has been approved in the United States and is being studied in various settings, including as first-line treatment and in combination with other TKIs.^[15][16]

Clinical trials are exploring optimal ways to achieve and maintain deep molecular responses that would allow more patients to attempt treatment-free remission. Some studies investigate whether combining TKIs with immune-modulating therapies might enhance the immune system’s ability to control residual leukaemia cells. The rationale is that if the immune system can be “trained” or boosted to recognise and eliminate CML cells, more patients might achieve lasting remission even after stopping medication.^[4]

Researchers are also studying the best strategies for monitoring patients in treatment-free remission. Different trials use varying schedules and thresholds for restarting treatment. Some investigate whether less frequent monitoring might be safe for patients who have been stable off treatment for extended periods, which would reduce the burden of repeated blood tests and clinic visits. Others examine molecular and immunological markers that might predict which patients are most likely to maintain remission without treatment.^[12]

Phase I, II, and III clinical trials for CML often focus on comparing newer TKIs with established ones, either as initial treatment or for patients whose disease has not responded adequately to first-line therapy. Phase I studies primarily assess safety and determine appropriate dosing. Phase II trials investigate whether the new treatment works effectively, typically measuring how quickly and deeply patients achieve molecular responses. Phase III studies compare new treatments directly with standard therapy to determine whether they offer meaningful advantages in terms of efficacy, side effects, or quality of life.^[16]

Clinical trials for CML are conducted worldwide, including in Europe, the United States, and many other countries. Eligibility depends on numerous factors including disease phase, previous treatments received, response to current therapy, genetic characteristics of the leukaemia cells, and overall health status. Patients interested in clinical trials should discuss options with their haematologist or oncologist, who can help identify appropriate studies and explain potential benefits and risks.

Most common treatment methods

• Tyrosine kinase inhibitors (TKIs)
  • Imatinib (first-generation TKI) – the original medication that transformed CML treatment, taken as a daily tablet
  • Dasatinib, nilotinib, bosutinib (second-generation TKIs) – more potent alternatives with different side effect profiles
  • Ponatinib (third-generation TKI) – effective against certain resistant forms of CML
  • Asciminib – a novel TKI targeting a different part of the BCR-ABL protein
  • All TKIs work by blocking the abnormal protein that drives CML cell growth
  • Treatment typically continues long-term or until criteria for treatment-free remission are met
• Regular molecular monitoring
  • PCR blood tests detect the BCR-ABL1 gene with high sensitivity
  • Testing frequency depends on treatment response and whether patient is on or off medication
  • Essential for assessing disease control and detecting early signs of relapse
  • Performed every month initially after treatment stops, gradually extending to every few months
• Treatment-free remission protocols
  • Available for patients who meet strict criteria after years of successful treatment
  • Requires intensive monitoring with frequent blood tests
  • Approximately half of eligible patients remain in remission without medication
  • Treatment can be safely restarted if molecular signs of disease return
• Supportive care measures
  • Management of TKI side effects including nausea, muscle pain, and fluid retention
  • Sun protection for patients on medications that increase photosensitivity
  • Regular monitoring of heart function, blood pressure, and other potential complications
  • Psychological support for managing the emotional impact of chronic disease

Maintaining Quality of Life While Managing CML in Remission

Living with CML in remission, whether on treatment or in treatment-free remission, requires ongoing attention to both physical and emotional wellbeing. Many people with well-controlled CML can maintain near-normal lives, but the reality of having a chronic condition—even one that is not immediately threatening—affects different aspects of daily existence.^[20]

Fatigue remains a common concern for people with CML, stemming from both the disease itself and treatment side effects. This is not ordinary tiredness but rather a profound exhaustion that can appear suddenly and persist despite rest. Evidence suggests that regular gentle exercise, such as walking, can help manage fatigue, though it is important to pace activities and avoid overexertion. Some patients find that fatigue affects their ability to work or study, requiring adjustments to schedules or responsibilities.^[21]

The emotional impact of CML extends beyond initial diagnosis. Even with excellent disease control, many people experience ongoing anxiety about test results, concern about potential relapse, and uncertainty about the future. Unlike cancers that can be declared “cured” after a certain period, CML requires indefinite monitoring and often lifelong awareness of the disease. This can create a sense of loss for one’s previous, carefree life. Some patients struggle with the invisibility of their illness—looking healthy while managing a serious condition can make it difficult to seek support or communicate struggles to others.^[20]

Regular medical appointments and blood tests become part of life with CML. For those on treatment, this typically means seeing a specialist every few months and having blood work done at similar intervals. For patients attempting treatment-free remission, the schedule intensifies considerably, particularly in the first year off medication. These frequent medical encounters serve the crucial purpose of detecting any disease activity early but can also feel burdensome and anxiety-provoking.^[7]

Financial considerations also affect quality of life. TKIs are expensive medications, and even with insurance coverage, out-of-pocket costs can be substantial. The need for regular blood tests and specialist visits adds to the financial burden. For patients in treatment-free remission, medication costs disappear but testing costs continue. Access to financial assistance programmes and understanding insurance coverage becomes important for managing these expenses.^[18]

Relationships with family and friends may shift as people navigate life with CML. Loved ones often need help understanding what CML means, why treatment continues even when the patient looks well, and how to provide appropriate support. Open communication about feelings, symptoms, and concerns helps both patients and their support networks adapt to the changed circumstances. Some people find that joining support groups, either in person or online, provides valuable connection with others who understand the unique challenges of living with CML.^[20]